tom_luedde Profile Banner
Tom Luedde Profile
Tom Luedde

@tom_luedde

Followers
2K
Following
4K
Media
62
Statuses
520

Clinician scientist @UniklinikDUS. Working on molecular and clinical aspects of liver disease and GI cancer. Views are my own. #livertwitter

Düsseldorf / Germany
Joined February 2017
Don't wanna be here? Send us removal request.
@tom_luedde
Tom Luedde
1 month
RT @LuddeMark: SGLT2 inhibitors may be good for your heart in many ways. Here is one of them @SamuelSossalla @UKGM….
0
3
0
@tom_luedde
Tom Luedde
1 month
RT @PeltzerNieves: Another great meeting coming up this year!. @tom_luedde.
0
2
0
@tom_luedde
Tom Luedde
2 months
Thanks to all speakers and the audience for a lively discussion! Fantastic opportunities for #ai but potential bias has to be considered and validation in trials needed! @EASLnews @EASLedu @HHU_de.
@EASLedu
EASL Education
2 months
At #EASLCongress, experts explored how can #AI shape the future of liver cancer care:.🧬 Deep learning in histopathology & imaging.📈 LLMs in liver cancer prediction: breakthrough or illusion? .⚖️ Ethical implementation: the EASL way .Key points on calibration, data quality &
Tweet media one
Tweet media two
0
2
20
@tom_luedde
Tom Luedde
4 months
We found that activating programmed necrosis through genetic or pharmacological interventions might be an effective anti-cancer-strategy in pancreatic cancer. Thanks to all collaborators and funders! @CancerInflam @HHU_de @MaxReichertMD.
0
11
56
@tom_luedde
Tom Luedde
6 months
Thanks to all participants for a fantastic day of exciting Research! Thanks to @ReibergerThomas for your valuable Input and advice! @UniklinikDUS @MedHHU.
@ReibergerThomas
Thomas Reiberger
6 months
#LiverX. Retreat of the FUTURE clinician scientist program - funded by DFG and coordinated by .Prof @tom_luedde and Prof Michael Roden at Clinic Düsseldorf. Great Research - personally biased interest for .#BileAcid in Diastolic 🫀Dysfunction.#Necroptosis in #MASH
Tweet media one
Tweet media two
0
0
16
@tom_luedde
Tom Luedde
7 months
>1000 participants in our Workshop GI Oncology ! Many innovations from 2024 are summarized in practical cases. Thanks to all speakers for a fantastic day! @UniklinikDUS @UKKoeln @UniklinikBonn @UniklinikAachen @UniklinikEssen @Krebshilfe_Bonn @DKG_Berlin
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
0
21
@tom_luedde
Tom Luedde
7 months
RT @jnkath: NAKO is the🇩🇪 equivalent of UK Biobank… funded by @BMBF_Bund. Unfortunately, the „# publications per € invested“ for NAKO is ve….
0
6
0
@tom_luedde
Tom Luedde
9 months
Very proud of Christian Weigel who won the #dgvs teaching award for transforming teaching in Gastroenterology into the digital future. ⁦@HHU_de⁩ ⁦@MedHHU⁩ ⁦@DGVSJuGa⁩ ⁦@asta_hhu
Tweet media one
1
0
20
@tom_luedde
Tom Luedde
9 months
Thanks for the kind Invitation, very impressed by your and your colleagues‘ exciting Research in SFB TRR 353 @Uniklinik_Fr.
@Dhairya_Rajguru
Dhairya Rajguru
9 months
Excellent talk by @tom_luedde at @UniFreiburg on the cross talks of pathways followed by discussion on cell death & implications on cancer. It's exciting that scientists are working on understanding the phenomena I've always wanted to explore, and our thoughts align.
Tweet media one
1
0
8
@tom_luedde
Tom Luedde
10 months
Fantastic start of the International Conference on Tropical Medicine and Global Health organized by our very own Torsten Feldt and team. >500 participants from all over the world. @UniklinikDUS @HHU_de @DGVSJuGa @junite_e @UKKoeln thanks to all who helped and supported
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
2
7
@tom_luedde
Tom Luedde
10 months
Universität Düsseldorf: Leberkrebs: Die Fitness von Tumorzellen als Angriffspunkt für neue Therapien
0
1
14
@tom_luedde
Tom Luedde
10 months
Out in @JHepatology : KIF23 and miR-107 control replicative fitness in hepatocellular carcinoma and might be a new therap. target. Thanks to all collaborators and funders! @EASLedu @EASLnews @MedHHU @UniklinikDUS @CancerInflam @dfg_public @IfADo_info
Tweet media one
0
6
49
@tom_luedde
Tom Luedde
11 months
RT @C_V_Schneider: Excited to share our aMASLDing research on how machine learning uncovered dietary manganese might protect against hepati….
0
4
0
@tom_luedde
Tom Luedde
1 year
RT @Lynch_Syndrom: Frisch publiziert mit News zum #lynchsyndrom: #S3Leitlinie #endometriumkarzinom. Als Mandatsträgerin dabei: @SimoneWidha….
0
3
0
@tom_luedde
Tom Luedde
1 year
Happy to Share our work on #ferroptosis in liver disease: The ferroptosis mediator ACSL4 fails to prevent disease progression in mouse models of MASLD. Thanks to ⁦@Conrad_Lab⁩ and our colleagues from the ⁦@Ferroptosis2306⁩ ⁦@HHU_de
1
3
41
@tom_luedde
Tom Luedde
1 year
Why the hell did it take 3 times longer to get me in shape than the other panelists? Ah, yes, it is our #EASLStudio on AI, where the young rule!! #EASLCongress @jnkath @etrepo @EASLnews @EASLedu
Tweet media one
@EASLedu
EASL Education
1 year
#EASLStudio on AI is about to start at the Hepato Arena, #EASLCongress 2024. Join the discussion with leading experts and EASL AI Taskforce members ! . #LIVERTWITTER
Tweet media one
3
3
29
@tom_luedde
Tom Luedde
1 year
Very proud of our young and dedicated liver team from ⁦⁦@UniklinikDUS⁩ We had a great time at #easlcongress meeting old and new friends , new project ideas, collaborations etc. Thanks to ⁦@EASLnews⁩ ⁦@EASLedu⁩ ⁦@AleksanderKrag⁩ for a fantastic meeting.
Tweet media one
0
5
28
@tom_luedde
Tom Luedde
1 year
The most disruptive and fascinating Session at #easlcongress : thanks to ⁦@jnkath⁩ ⁦@C_V_Schneider⁩ and all speakers for giving us a glance at the opportunities of large language Models ⁦@EASLnews⁩ ⁦@EASLedu⁩ ⁦@UniklinikAachen⁩ ⁦@EKFZdigital
Tweet media one
0
7
55
@tom_luedde
Tom Luedde
1 year
RT @EASLnews: We are delighted to announce the introduction of the new AI Task Force! Members are @Caldera60373705, @jnkath, @tom_luedde, @….
0
17
0
@tom_luedde
Tom Luedde
1 year
RT @JesusMBanales: 1/🚀JHEP Journal Club🚀. 😲Chronic jet lag drives NAFLD-related liver cancer⁉️✈️🔓 Epidemiological s….
0
7
0